Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 8/20 | 0.41 |
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL908328 | 0.89 | LMNA (0.40) | CA1CA2L3MBTL1 | |
| SCHEMBL11060811 | 0.81 | PRKCZ (0.56) | PRKCZMAOBMAOACA1CA2 | |
| SCHEMBL11058379 | 0.79 | PRKCZ (0.57) | PRKCZCA1CA2L3MBTL1 | |
| SCHEMBL11060046 | 0.79 | PRKCZ (0.51) | PRKCZMAOBL3MBTL1 | |
| SCHEMBL908494 | 0.79 | CA1 (0.56) | PRKCZCA1CA2L3MBTL1EGFR | |
| SCHEMBL11068397 | 0.77 | PRKCZ (0.52) | PRKCZEGFRERBB2 | |
| SCHEMBL16139671 | 0.74 | MEN1 (0.40) | CA1CA2 | |
| SCHEMBL10846803 | 0.73 | PRKCZ (0.41) | PRKCZMAOBMAOAEGFRERBB2 | |
| SCHEMBL11094507 | 0.72 | PRKCZ (0.47) | PRKCZEGFR | |
| SCHEMBL11372777 | 0.71 | MAPT (0.41) | PRKCZMAOBMAOACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003862-A1 | 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases | MERCK SHARP & DOHME LIMITED (GB) | 2011-01-06 | — | — | US | claimed |
| EP-1987007-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LTD. (GB) | 2008-11-05 | — | — | EP | claimed |
| WO-2007093829-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-23 | — | — | WO | claimed |
| US-20110003862-A1 | 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases | MERCK SHARP & DOHME LIMITED (GB) | 2011-01-06 | — | — | US | disclosed |
| EP-1987007-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LTD. (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093829-A1 | 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003862-A1 | 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases | DAO, DDO, MAOA | PRKCZ 2127/4885MAOB 4/4885MAOA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.